Neutra Corp. (OTC: NTRR) (“Neutra” or “the Company”), fresh off the recent release of a new cannabidiol (CBD) sports cream, has not rested in its efforts to press forward on its global mission. The Company has executed a game changing letter of intent (LOI) that, if executed as planned, may lead to the joint development of a wide variety of additional hemp-based medicinal products to serve the rapidly growing CBD market – a segment some analysts have predicted will soar to $11 billion by 2026.
When completed, the agreement with Harrisburg, PA, based Orgaceutical Co would provide Neutra access to Orgaceutical’s formal research findings to investigate the use of cannabinoids as antioxidants and neuro-protectants. Neutra would also gain rights to a federally registered hemp trademark as well as a license for hemp cultivation issued by the Commonwealth of Pennsylvania’s Department of Agriculture.
“This LOI will propel us into an excellent position for research and development of exciting new applications for hemp-based medicinal CBD products,” said Sydney Jim, Neutra’s CEO. “With the cultivation license, we’ll have a constant and consistent supply of quality hemp under a vertically integrated cultivation model. With the research license, we’ll be free to explore new uses for hemp and products derived from it. Finally, with the trademark, we’ll have a federally protected brand name to pair with our existing VIVIS product line.”
The noted investing website Motley Fool has predicted U.S. sales of CBD products will more than double every year between 2019 and 2023. Bloomberg has called hemp the “cannabis cash crop” thanks to the booming demand for the non-psychoactive CBD that can be derived from it. CBD is low in THC, the compound that gets users high. Because of its low THC level, hemp-based CBD is finding mainstream acceptance among a public eager for its medicinal value but not wanting the high that comes with other forms of cannabis.
The LOI represents the latest step in Neutra’s efforts to become a vertically integrated company. The Company’s rapid forward progress in 2019 recently led Neutra to cancel a planned reverse split, which had become unnecessary amid so much recent traction.
About Neutra Corp.
Neutra Corp. (NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture—one wherein which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company’s website at www.NeutraInc.com.
NOTICE REGARDING FORWARD LOOKING STATEMENT
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
View Source On Www.Globenewswire.com
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com